Stereotaxis

Stereotaxis FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Stereotaxis (STXS) as of Oct 11, 2026 is 63.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 35.48 % — a change of 79.43% (higher).

FCF Conversion

63.66 %

YoY

79.43%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Stereotaxis is 2025 63.66 % . FCF Conversion Rate (FCF/EBITDA) of Stereotaxis was 2024 35.48 % . It decreases by 79.43% higher compared to the previous year.

The Stereotaxis FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-2,408.50 USD
Jan 1, 2019
109.76 USD
Jan 1, 2020
55.52 USD
Jan 1, 2021
40.53 USD
Jan 1, 2022
56.36 USD
Jan 1, 2023
45.89 USD
Jan 1, 2024
35.48 USD
Jan 1, 2025
63.66 USD
The Stereotaxis FCF Conversion history
YEARFCF ConversionYoY
63.66 %+79.43%
35.48 %-22.68%
45.89 %-18.57%
56.36 %+39.06%
40.53 %-27.00%
55.52 %-49.42%
109.76 %-104.56%
-2,408.50 %-3,081.37%
80.78 %-38.75%
131.90 %+261.64%
36.47 %-79.41%
177.15 %—
Access this data via the Eulerpool API

Stereotaxis Stock analysis

What does Stereotaxis do? Stereotaxis Inc, based in St. Louis, Missouri, is a company that specializes in the development and marketing of advanced instruments and services in magnetic resonance imaging (MRI) and electrophysiology (EP). The company was founded in 1990 and its mission is to improve the accuracy, safety, and efficiency of MRI and EP procedures. The business model of Stereotaxis is based on providing a comprehensive range of systems, instruments, and services to support hospitals and clinics in performing MRI and EP procedures. The company focuses on developing innovative technologies and solutions to improve clinical outcomes and provide the best possible treatment for patients. The company has four main divisions: magnetic resonance imaging (MRI), electrophysiology (EP), cardiovascular diagnostics, and cardiology. In the MRI division, the company offers a variety of instruments and systems specifically designed for MRI procedures. This includes magnetic field control systems, imaging systems, sample collection and analysis instruments, and controls to make MRI procedures more efficient. In the electrophysiology division, Stereotaxis offers instruments and systems that facilitate the navigation and control of medical devices during EP procedures. This includes magnetic field controls and other technologies to improve the accuracy of catheter placement and increase safety during procedures. Stereotaxis's cardiovascular diagnostics division offers various services and technologies that facilitate the performance of cardiology procedures. This includes a comprehensive diagnostic platform that allows for the analysis of heart images. The cardiology division of Stereotaxis offers a comprehensive range of solutions to improve the performance of cardiology procedures in cardiology clinics and hospitals. This includes a range of technologies to improve the diagnosis and treatment of heart diseases. In recent years, Stereotaxis has developed a variety of innovative solutions and technologies to improve the performance of MRI and EP procedures. One example is Robotic Magnetic Navigation, a technology developed by the company to improve the accuracy and safety of EP procedures. This technology allows doctors to improve the navigation and control of catheters during procedures, thereby providing patients with increased treatment safety. Another example is Stereotaxis's Odyssey platform, a solution developed to enable real-time connectivity between various medical devices. This allows doctors to access a variety of information during procedures and make the performance of procedures more efficient. Overall, Stereotaxis has an impressive track record in the development and marketing of advanced solutions and technologies in the MRI and EP industry in recent years. With its innovative technology and comprehensive range of instruments and services, the company is well positioned to continue playing a key role in healthcare in the future. Stereotaxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stereotaxis stock

FCF Conversion Rate (FCF/EBITDA) of Stereotaxis is 63.66 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Stereotaxis changed from 35.48 % to 63.66 %, representing a 79.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Stereotaxis since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Stereotaxis with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Stereotaxis

All Key Metrics — Stereotaxis